On October 15, 2024, GeneMind hosted the “2024 Life Omics Innovation Ecosystem Conference and GeneMind New Product Launch” in Nanjing, Jiangsu province. With the theme “Sequencing Powerhouse: Unlocking the Genetic Potential”, the event

GeneMind has collaborated with QIAGEN to validate multiple mature NGS solutions from QIAGEN based on the GeneMind SURFSeq 5000* and GenoLab M* sequencing platforms. The test results demonstrate high compatibility between the GeneMind sequencing platforms and

Genetic sequencers in modern molecular diagnostics and research employ Next-generation Sequencing tests to decode DNA or RNA sequences. Hence, they enable precise genetic analysis for disease diagnosis, personalized medicine, and evolutionary

DNA sequencers in modern molecular diagnostics empower precise decoding of genetic material for understanding genetic disorders and developing targeted therapies. GeneMind Biosciences, or GeneMind, shines in these technologies and focuses

Precision medicine is a personalized healthcare approach that uses genetic, environmental, and lifestyle factors for patient treatment. Crucially, targeted sequencing is key in this paradigm to identify specific genetic mutations

The field of genetic evaluation has the potential to undergo a paradigm shift due to Next Generation Sequencing(NGS), also referred to as the next generation sequencing test. A significant advancement

GeneMind has raised nearly RMB 400 million in a Series C funding round, which it will put toward expanding the research and development of its products and applications, broadening the

On November 28, GeneMind officially launched the third self-developed sequencing system FASTASeq 300. GeneMind showcased the instrument at Medlab Middle East 2023, making its first worldwide debut at booth Z1.B39,

On March, GeneMind and Nanjing Jiangbei New District have reached a strategic partnership. The cooperation mainly focuses on promoting the industrialization and development of high-throughput sequencing technology. The two parties